Spyre Therapeutics, Inc.

Healthcare · Biotechnology · United States

Last price 98.96 USD (Oct 29, 2026, 4:00 PM EDT) · Market cap 9.25B

Overview · Financial statements · Key statistics · Dividends · Company profile · Price history · Reports

Spyre Therapeutics, Inc., a clinical stage biotechnology company, focuses on developing therapeutics for patients living with inflammatory bowel disease (IBD) and rheumatic diseases. The company develops SPY001, a humanized monoclonal immunoglobulin G1 antibody that is in phase-2 clinical stage designed to bind selectively to the α4β7 integrin being developed for the treatment of IBD (ulcerative colitis and Crohn’s disease); and SPY002 and SPY072 – anti-TL1A mAbs designed to bind to tumor necrosis factor-like ligand 1A (TL1A). It is also develo...